

Introducing the Notification Form for Genom Editing in (GE_d) Plants (Contained use activity)



Session Objective


Objective of this session is to introduce the workflow and form for Genome Edited Plants in Contained Use Activities for Exemption by Minister

PENGECEUALIAN OLEH MENTERI

DALAM menjalankan kuasa yang diberikan oleh seksyen 68 Akta Biokeselamatan 2007 [Akta 678], Menteri, atas syor Lembaga, mengecualikan daripada keperluan Bahagian IV Akta bagi aktiviti pengeksportan, kegunaan terkawal dan pengimportan untuk kegunaan terkawal organisma diubah suai yang hidup (tumbuhan) melibatkan penyuntingan genom dan perlu dipantau oleh jawatankuasa keinstitusian biokeselamatan organisasi yang berdaftar. Penyuntingan genom tumbuhan berikut dikecualikan -

1. sebarang aktiviti yang melibatkan *Site-Directed Nuclease 1 (SDN-1)*; dan
2. sebarang aktiviti yang melibatkan *Site-Directed Nuclease 2 (SDN-2)* dan penyelitan 20 pasangan bes atau kurang asid deoksiribonukleik (DNA).

Tarikh 7 Mei 2025
[JBK(S)100-5/1/1 Jld. 6 (8)]



NIK NAZMI BIN NIK AHMAD
Menteri Sumber Asli dan Kelestarian Alam

EXEMPTION BY MINISTER

IN exercise of the powers conferred by section 68 of the Biosafety Act 2007 [Act 678], the Minister, upon recommendation of the Board, exempts from the requirements of Part IV of the Act for exportation, contained use activities and import for contained use activities for living modified organism (plants) involving genome editing and monitored by the registered organization's institutional biosafety committee. The following genome editing of plants is exempted –

1. any activity involving Site-Directed Nuclease 1 (SDN-1); and
2. any activity involving Site-Directed Nuclease 2 (SDN-2) and the insertion of 20 base pairs or less deoxyribonucleic acid (DNA).

Dated 7 May 2025
[JBK(S)100-5/1/1 Jld. 6 (9)]



NIK NAZMI BIN NIK AHMAD
Minister of Natural Resources and
Environmental Sustainability

Why This Form Matters



Biosafety & Governance

Supports biosafety governance



Facilitates exemption evaluation for eligible genome editing activities



Oversight & Responsibility

Supports institutional oversight via IBC



Promotes responsible innovation in plant genome editing within a clear regulatory framework



Documentation & Quality

Encourages high-quality documentation

Regulatory Context



Scope of Application

Applies to contained use, import for contained use and export of plants.



Oversight Body

Monitored by IBC (similar to how exempted activities under First schedule is currently being monitored by IBC).



Exemption Eligibility

Criteria must be met




Techniques Covered

- SDN-1
- SDN-2 (≤ 20 bp)

Does Your Activity Qualify?

Exemption Eligibility

SDN-1




Site-Directed
Nuclease-1



Exempted
Activities

SDN-2

(≤ 20 bp insertion)



Site-Directed Nuclease-2
(limited insertion)



Important Note: Non-Exempt Activities

If your activity does not qualify for exemption,
submit Form E to JBK via IBC



Overview of the Form Structure



Section A: PI / Person-in- Charge details

IBC contact information and principal investigator's details.



Part I: Project Information

Purpose, objectives, and duration of the research.



Part II: Description of the GE Plant

Scientific name, edited trait, and phenotypic changes.



Part III: Editing Procedure & Tools

Specific gene editing methods, tools, and delivery systems used.



Part IV: Nature of DNA Changes

Details on target gene, mutation type, size, and sequence alignment.



Part V: Imported GE Plant (if applicable)

Declaration of regulatory status and import details.

Introduction Notification Form: GEd Plants - Workflow

Submission Workflow & Guidance

Step-by-Step Submission Workflow



1. Self-Assessment
(Confirm SDN-1/
SDN-2 \leq 20bp)



2. Documentation
(Prepare Appendix
& Flowchart)



3. Submission
(Submit to IBC,
Declare Accuracy)



4. Outcome
(IBC Review)



IBC Review & Possible Outcomes


IBC Review, ID Assigned.
Decision: Exempted or Non-Exempted
(Requires JBK Notification)



Common Pitfalls to Avoid

Incomplete Descriptions, Unclear Mutation,
Missing Appendix, Inconsistent Methods,
>20bp (SDN-2)

FLOW CHART



Part I – Project Information



Purpose of activity (research, teaching, etc.)



Project title and duration



Brief summary (≤ 200 words)



Optional: flowchart as appendix



Clear objectives and expected outcomes are essential

Part I – Project Information



Part I: Project Information

1.	Purpose: (Please tick the options that apply.)	<input type="checkbox"/> Research <input type="checkbox"/> Teaching <input type="checkbox"/> Lab Service <input type="checkbox"/> Commercial <input type="checkbox"/> Storage <input type="checkbox"/> Others (Specify): Click or tap here to enter text. _____
2.	Activity/Project Title:	Click or tap here to enter text.
3.	Start Date and End Date:	Click or tap here to enter text.
4.	Brief summary of the activity/project (if applicable, please include general objective, research methodology and expected outcome) not exceeding 200 words. (You may include a flowchart in addition to the narrative above as an appendix.)	

Part II – Description of the GEd Plant



Scientific and common name



Purpose of the edited trait

before



Phenotypic features before editing

after



Phenotypic features after editing



Focus on measurable and observable changes

Part II – Description of the GEd Plant

Part II. Description of the Genome Edited (GEd) Plant

Name of the GEd Plant	Scientific Name:
	Common Name:
Purpose of the GEd plant (e.g. improved trait, pest resistant, improved nutritional value, etc.)	
Phenotypic features before and after genetic change	Before Genetic Change:
	After Genetic Change:

Part III – Genome Editing Procedure



Type of genetic change (SDN-1 or SDN-2 ≤ 20 bp)



Gene editing tools used (e.g., CRISPR, TALEN, Zinc Finger)



Delivery system (*Agrobacterium*, biolistic, PEG, floral-dip, etc.)



Ensure consistency between method and reported mutation

Part III. Description of the GEd Plant Procedure

Type of genetic change in the organism	<input type="checkbox"/> Site-directed nuclease 1 (SDN1) <input type="checkbox"/> Site-directed nuclease 2 (SDN2), ≤ 20 bp
Gene editing tool(s) used	<input type="checkbox"/> CRISPR <input type="checkbox"/> Zinc finger <input type="checkbox"/> TALEN <input type="checkbox"/> Other: _____
Delivery System	<input type="checkbox"/> Agrobacterium-mediated <input type="checkbox"/> Particle bombardment/biolistic method <input type="checkbox"/> Floral-dip <input type="checkbox"/> PEG-mediated protoplast method <input type="checkbox"/> Other (specify): _____

Part IV – Nature of DNA Changes



Identify gene(s) targeted



Describe gene product and function



Specify target site location (bp)

A→T

Type of mutation (insertion, deletion, substitution)



Size of change (bp)



Include sequence alignment appendix

Part IV: Nature of DNA changes

(if more than 1 gene involved, please add more rows as needed)

***For SDN-2, Provide as appendix the alignment of sequences before and after genetic editing.**

Please ensure the changes are indicated clearly.

1.	Gene 1				
2.	Product of gene				
3.	Function				
4.	Effect of Gene Editing				
5.	Target site	1	2	3	4
	Site location (bp)				
	Type of mutation (e.g.: insertion, deletion, substitution, etc.)				
	Size of changes (bp)				

Example of PART IV- Nature of DNA Changes



4.0 Example of Appendix of the Alignment of Sequences Before and After Genetic Editing

a. SDN-1 with single gene modification (with -2 bp deletion)

CLUSTAL O(1.2.4) multiple sequence alignment

```
WT      tatgtccaagacattggagagataccacagatacaattatggtacacttgaaggaaccca    60
GE      tatgtccaaga--cattggagagaccacagatacaattatggtacacttgaaggaaccca    58
*****          **** *****

WT      aacttcatcagattcacag      79
GE      aacttcatcagattcacag      77
*****
```

b. SDN-2 with one gene modification (with 1 bp substitution)

CLUSTAL O(1.2.4) multiple sequence alignment

```
WT      tatgtccaagacattggagagataccacagatacaattatggtacacttgaaggaaccca    60
GE      tatgtccaagacattcgagagataccacagatacaattatggtacacttgaaggaaccca    60
***** *****

WT      aacttcatcagattcacag      79
GE      aacttcatcagattcacag      79
*****
```

Part V – Imported GE Plants (If Applicable)

- Declare regulatory status in issuing country
 - Describe precedent decisions (if any)
 - Ensure documentation supports exemption claim

Part V : For Imported GEd Plant

1. Any existing regulatory precedence on the GEd plant in the issuing country and purpose of the decision (if applicable).

FAQ


QUESTION 1

Why is gene editing not mentioned in Biosafety Act 2007?

ANSWER

The Biosafety Act was drafted **prior to the year 2007**. CRISPR-Cas9 technology for gene editing was developed in 2012. However it is covered in the definition of **modern biotechnology, in vitro techniques**.

FAQ



QUESTION 2

If all the criteria for exemption are met, do the applicants still need to fill the form E?

ANSWER

Not required. Only **fill in the Notification Form for Genome Editing in Plants.**

FAQ

QUESTION 3


Is sequencing alignment mandatory to be provided as basis for exemption ?

ANSWER

SDN- 1 – Not mandatory.

SDN-2 - Yes, the alignment of sequences before and after genome editing at the target site must be provided.

FAQ



QUESTION 4


Where can I get the form for exemption of activities involving gene edited plants for contained used activities?

ANSWER

It will be made available on the **JBK website**.

It will be **emailed out to all BSO/ IBC Chair**.

FAQ



QUESTION 5

Is the exemption applicable for all plant species?

ANSWER

Yes, this exemption is applicable for **all plant species**.

FAQ

QUESTION 6

How long does it take for the exemption process to be approved?

ANSWER

Dependent of respective IBC's processing time.

Delays are caused

- if documents are not complete
- there are queries

Suggested for IBC to target processing time of 30 days.

FAQ

QUESTION 7

Can exempted plants be transported between premises?

ANSWER

Yes, however the recipient facility's **IBC must be informed** of the movement of gene edited plants.

FAQ

QUESTION 8

If the plant is exempted, can it also be exempted for field trial?

ANSWER

No, this **exemption is not in place yet**, and for now, it has to still be regulated as an LMO.

QUESTION 9

The outcome of SDN-1 editing is random, and the exact sequence changes will not be known until the gene edited plant has been characterized.

How should the form be filled up before starting the activity?

ANSWER

SDN1 – Random. **Include information about where they are targeting and the number of sites and indicate the possible type of mutation (e.g., deletion or insertion).**

A follow-up report detailing the correct mutation can be submitted to the IBC once the GE lines are constructed/characterized.

SDN2 – Precise. Researchers can fill in the predicted mutation.

QUESTION 10

What if there are off targets detected, does this affect the exemption status?

ANSWER

IBC Exemption is based on information provided in the form.

If the gene edited plant has characteristics not mentioned in the Form, it will have to be re-evaluated.

If there is integration of foreign DNA (e.g. vector sequences) into the plant genome, then it becomes an LMO (novel gene present), and proceed to submit Form E.

FAQ

QUESTION 11

Can ongoing activities (notifications that have been submitted to JBK) be exempted?


ANSWER

There will be **no backdate exemptions.**

Ongoing activities will be regulated as LMOs.

Activities currently being assessed by IBC - ?

FAQ



QUESTION 12

When do we start using these forms?

ANSWER

5 March 2026

FAQ

QUESTION 13

When reporting exempted contained use activity of gene edited plants, do the forms need to be submitted together with the Annual IBC Report?

ANSWER

No, the form is for IBC's internal record purposes.

JBK **may request to review** the forms.

The Annual IBC Report will contain a **separate section** to fill for exempted contained use activities involving gene edited plants.

FAQ

QUESTION 14

After starting the activity, it was found that it is more than 20 base pairs and no longer exempted, what should the researcher do?

ANSWER

Researcher should inform the IBC immediately and provide the details. IBC is to inform JBK immediately and will be provided with further instructions.

FAQ

QUESTION 15

Is there are several SDN1 edit sites, is there a limitation of how many sites can be done? Is there a limit on how many base pairs per edit site?

ANSWER

For contained use activity, there is no limit to how many edit sites you can do.

There is a limit of 20 base pairs for each SDN1 site.

Example – you may have 30 SDN1 insertions of 18 bps length for each site.